Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113390 | 0.86 | KMT2A (0.73) | MEN1KMT2APOLBLMNAHTT | |
| SCHEMBL7378432 | 0.84 | HTT (0.50) | MEN1KMT2APOLBLMNAHTT | |
| SCHEMBL10280223 | 0.82 | MEN1 (0.79) | MEN1KMT2APOLBLMNAATM | |
| SCHEMBL7656196 | 0.80 | ADRA1A (0.57) | MEN1KMT2APOLBLMNAATM | |
| SCHEMBL7667781 | 0.80 | ADRA1A (0.57) | MEN1KMT2APOLBLMNAATM | |
| SCHEMBL7667964 | 0.80 | ADRA1A (0.57) | MEN1KMT2APOLBLMNAATM | |
| SCHEMBL6348122 | 0.77 | HTT (0.75) | POLBHTTKIF11ALDH1A1 | |
| SCHEMBL9763191 | 0.76 | GRIN2B (0.43) | MEN1KMT2APOLBLMNAHTT | |
| SCHEMBL10440386 | 0.76 | GRIN2B (0.43) | MEN1KMT2APOLBLMNAHTT | |
| SCHEMBL14164091 | 0.73 | KIF11 (0.79) | MEN1KMT2APOLBLMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855716-B2 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO. INC (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1193259-A1 | DIHYDROPYRIMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | CACNA1B, CACNA1D, CACNA1G | MEN1 2062/4885KMT2A 4414/4885POLB 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.